Open AccessRecent advances in artificial intelligence for pancreatic ductal adenocarcinoma
Author(s) -
Hiromitsu Hayashi,
Naomi Uemura,
Kazuki Matsumura,
Lei Zhao,
Hiroki Sato,
Yuta Shiraishi,
Yoichi Yamashita,
Hideo Baba
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i43.7480
Subject(s) - pancreatic ductal adenocarcinoma , big data , precision medicine , subtyping , disease , pancreatic cancer , artificial intelligence , medicine , exploit , computer science , data science , machine learning , bioinformatics , cancer , pathology , data mining , biology , computer security , programming language
Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal type of cancer. The 5-year survival rate for patients with early-stage diagnosis can be as high as 20%, suggesting that early diagnosis plays a pivotal role in the prognostic improvement of PDAC cases. In the medical field, the broad availability of biomedical data has led to the advent of the "big data" era. To overcome this deadly disease, how to fully exploit big data is a new challenge in the era of precision medicine. Artificial intelligence (AI) is the ability of a machine to learn and display intelligence to solve problems. AI can help to transform big data into clinically actionable insights more efficiently, reduce inevitable errors to improve diagnostic accuracy, and make real-time predictions. AI-based omics analyses will become the next alterative approach to overcome this poor-prognostic disease by discovering biomarkers for early detection, providing molecular/genomic subtyping, offering treatment guidance, and predicting recurrence and survival. Advances in AI may therefore improve PDAC survival outcomes in the near future. The present review mainly focuses on recent advances of AI in PDAC for clinicians. We believe that breakthroughs will soon emerge to fight this deadly disease using AI-navigated precision medicine.